[go: up one dir, main page]

BE2015C072I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C072I2
BE2015C072I2 BE2015C072C BE2015C072C BE2015C072I2 BE 2015C072 I2 BE2015C072 I2 BE 2015C072I2 BE 2015C072 C BE2015C072 C BE 2015C072C BE 2015C072 C BE2015C072 C BE 2015C072C BE 2015C072 I2 BE2015C072 I2 BE 2015C072I2
Authority
BE
Belgium
Application number
BE2015C072C
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BE2015C072I2 publication Critical patent/BE2015C072I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BE2015C072C 2003-09-29 2015-12-09 BE2015C072I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (1)

Publication Number Publication Date
BE2015C072I2 true BE2015C072I2 (nl) 2023-12-14

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C072C BE2015C072I2 (nl) 2003-09-29 2015-12-09

Country Status (33)

Country Link
US (2) US7250170B2 (nl)
EP (1) EP1673106B1 (nl)
JP (4) JP5451960B2 (nl)
KR (1) KR101165278B1 (nl)
CN (1) CN1859923B (nl)
AR (2) AR045804A1 (nl)
AT (1) ATE435029T1 (nl)
AU (1) AU2004277934B2 (nl)
BE (1) BE2015C072I2 (nl)
BR (1) BRPI0414845B8 (nl)
CA (1) CA2539168C (nl)
CY (2) CY1110525T1 (nl)
DE (1) DE602004021828D1 (nl)
DK (1) DK1673106T3 (nl)
ES (1) ES2327530T3 (nl)
FR (1) FR15C0083I2 (nl)
HU (1) HUS1500063I1 (nl)
IL (1) IL174458A (nl)
IS (1) IS2694B (nl)
LT (2) LTPA2015049I1 (nl)
LU (1) LU92902I2 (nl)
MX (1) MXPA06003457A (nl)
MY (1) MY140664A (nl)
NL (1) NL300776I1 (nl)
NO (3) NO339932B1 (nl)
NZ (1) NZ545834A (nl)
PL (1) PL1673106T3 (nl)
PT (1) PT1673106E (nl)
RU (1) RU2360001C2 (nl)
SI (1) SI1673106T1 (nl)
TW (1) TWI350853B (nl)
WO (1) WO2005032586A1 (nl)
ZA (1) ZA200601961B (nl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
RU2373219C2 (ru) 2004-03-24 2009-11-20 Мерк энд Ко. Инк. Оптимизированная экспрессия hpv 52 l1 в дрожжах
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
EP2059262B1 (en) * 2006-08-28 2013-08-21 Sungkyunkwan University Foundation for Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
MX344751B (es) 2007-11-23 2017-01-05 Shanghai Zerun Biotechnology Co Ltd Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos.
MX2011013566A (es) 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
WO2012173390A2 (ko) * 2011-06-15 2012-12-20 중앙대학교 산학협력단 인유두종바이러스 l1 단백질의 생산 수율을 향상시키는 방법
CA2834618C (en) 2011-06-24 2020-11-03 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110295190A (zh) * 2013-05-17 2019-10-01 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280793B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因,及载体,菌株,表达方法
CA2927434C (en) 2013-10-16 2022-07-19 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
JP2023516904A (ja) 2020-02-14 2023-04-21 メルク・シャープ・アンド・ドーム・エルエルシー Hpvワクチン
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法
WO2024254226A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0757717T3 (da) * 1994-05-16 2006-09-25 Merck & Co Inc Papillomavirusvacciner
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
CN1252075A (zh) 1997-02-07 2000-05-03 麦克公司 合成的hiv gag基因
WO1998054339A1 (en) * 1997-05-27 1998-12-03 Hanil Synthetic Fiber Co., Ltd. PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE)
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
CA2339324C (en) * 1998-08-14 2011-05-31 Robert S. Lowe Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
EP1140974B1 (en) * 1998-12-23 2005-03-02 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
IL154009A0 (en) 2000-07-21 2003-07-31 Glaxo Group Ltd Codon-optimized papilloma virus sequences
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP4505452B2 (ja) 2003-03-24 2010-07-21 メルク・シャープ・エンド・ドーム・コーポレイション 酵母におけるhpv31l1の最適化発現

Also Published As

Publication number Publication date
CN1859923B (zh) 2012-09-05
PT1673106E (pt) 2009-09-22
CN1859923A (zh) 2006-11-08
NO2022051I1 (no) 2022-11-30
TWI350853B (en) 2011-10-21
DK1673106T3 (da) 2009-11-09
NL300776I2 (nl) 2015-12-29
CA2539168C (en) 2011-05-31
ATE435029T1 (de) 2009-07-15
JP2014221052A (ja) 2014-11-27
TW200521233A (en) 2005-07-01
HUS1500063I1 (hu) 2016-02-29
US20060240040A1 (en) 2006-10-26
IL174458A0 (en) 2006-08-01
JP5451960B2 (ja) 2014-03-26
US7482015B2 (en) 2009-01-27
BRPI0414845B8 (pt) 2021-06-15
NO339932B1 (no) 2017-02-20
JP2007507207A (ja) 2007-03-29
AU2004277934A1 (en) 2005-04-14
RU2006114701A (ru) 2007-11-10
NL300776I1 (nl) 2015-12-29
CY2015050I2 (el) 2016-06-22
LTPA2015049I1 (lt) 2016-01-11
MXPA06003457A (es) 2006-06-05
BRPI0414845B1 (pt) 2020-10-13
EP1673106A1 (en) 2006-06-28
JP2016136947A (ja) 2016-08-04
AU2004277934B2 (en) 2009-09-17
DE602004021828D1 (de) 2009-08-13
LU92902I2 (fr) 2016-03-08
US7250170B2 (en) 2007-07-31
BRPI0414845A (pt) 2006-11-21
EP1673106B1 (en) 2009-07-01
LTC1673106I2 (lt) 2017-05-10
PL1673106T3 (pl) 2009-12-31
CY2015050I1 (el) 2016-06-22
MY140664A (en) 2010-01-15
US20080138361A1 (en) 2008-06-12
IS2694B (is) 2010-11-15
AR077396A2 (es) 2011-08-24
IL174458A (en) 2014-06-30
SI1673106T1 (sl) 2009-12-31
NO20061876L (no) 2006-04-28
NO2017012I1 (no) 2017-04-05
ZA200601961B (en) 2007-05-30
AR045804A1 (es) 2005-11-16
IS8362A (is) 2006-03-20
FR15C0083I2 (fr) 2016-11-25
WO2005032586A1 (en) 2005-04-14
ES2327530T3 (es) 2009-10-30
JP2011152137A (ja) 2011-08-11
RU2360001C2 (ru) 2009-06-27
KR101165278B1 (ko) 2012-07-23
KR20070029628A (ko) 2007-03-14
CA2539168A1 (en) 2005-04-14
FR15C0083I1 (fr) 2016-08-01
NZ545834A (en) 2009-02-28
CY1110525T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
BE2015C072I2 (nl)
BE2013C075I2 (nl)
BE2013C069I2 (nl)
BE2013C067I2 (nl)
BE2013C038I2 (nl)
BE2013C036I2 (nl)
BE2011C030I2 (nl)
JP2004209042A5 (nl)
IN2006CH00859A (nl)
BE2013C034I2 (nl)
JP2004041732A5 (nl)
JP2004011638A5 (nl)
JP2004044578A5 (nl)
BE2012C053I2 (nl)
IN226755B (nl)
JP2004223829A5 (nl)
JP2004009736A5 (nl)
JP2004222640A5 (nl)
JP2004221218A5 (nl)
JP2003283999A5 (nl)
JP2004106937A5 (nl)
JP2004109986A5 (nl)
AU2002322913A1 (nl)
AU2002355123A1 (nl)
AU2002331433A1 (nl)